Login to Your Account



Skin tight: Debt hits derm, quiz Valeant 'core' values in $2B-plus assets sell-off

By Randy Osborne
Staff Writer

Tuesday, January 10, 2017
deals_and_ma.jpg

During a third-quarter earnings conference call in November with investors, when asked about divestitures that could help the company chip away at major debt and focus on the main business, Valeant Pharmaceuticals International Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription